Compare McKesson Corporation (MCK) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Texas Instruments Incorporated — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Texas Instruments Incorporated trades at $292.62 (market cap $258.53B). The key difference: Texas Instruments Incorporated is far larger — about 2.7× McKesson Corporation's market cap, and Texas Instruments Incorporated pays the higher dividend (2%). Which is the better fit depends on your goals.
| MCK | TXN | |
|---|---|---|
Market Cap | $97.35B | $258.53B |
Sector | Health | Technology |
52-Week High | $995.69 | $332.35 |
52-Week Low | $659.01 | $153.33 |
Enterprise Value | $101.98B | $267.48B |
Dividend Yield | 0.39% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Texas Instruments (TXN) trades at $284.07, showing minimal daily movement (+0.02%). The stock demonstrates strong profitability with 29.11% net margins and 32.18% ROE, though valuation metrics appear elevated with a P/E of 48.55. Recent Q1 2026 earnings beat expectations at $1.68 EPS versus $1.36 expected, while technical indicators show bearish momentum despite crossing above the 20-day moving average according to Zacks (June 3, 2026).
The company faces mixed signals with improving operational cash flow ($7.15B in 2025) and AI-driven demand growth offset by declining profit margins and rising debt levels. Analyst consensus remains positive with a $317.20 price target, though technical weakness and competitive pressures in semiconductors present near-term headwinds for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
